Next Article in Journal
Forward Genetic Screens as Tools to Investigate Role and Mechanisms of EMT in Cancer
Next Article in Special Issue
Epigenetic Insights on PARP-1 Activity in Cancer Therapy
Previous Article in Journal
Long Intergenic Non-Protein Coding RNA 173 in Human Cancers
Previous Article in Special Issue
Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 23
10.3390/cancers14235922
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer

Cancers 2022, 14(23), 5922; https://doi.org/10.3390/cancers14235922
by Andrisha-Jade Inderjeeth 1, Monique Topp 1, Elaine Sanij 1,2,3,4, Elena Castro 5 and Shahneen Sandhu 1,2,*
Reviewer 1: Anonymous
Cancers 2022, 14(23), 5922; https://doi.org/10.3390/cancers14235922
Submission received: 2 November 2022 / Revised: 23 November 2022 / Accepted: 23 November 2022 / Published: 30 November 2022
(This article belongs to the Special Issue Clinical Use of PARP Inhibitors in Cancer – From Bench to Bedside and Back Again)

Round 1

Reviewer 1 Report

The authors provided a comprehensive review of the trials with PARP inhibitors in CRPC patient cohorts, both mono therapy trials and combinatorial trails are presented. The review is thorough and provided intensive information on the current progress of the trial results. In addition, the authors also discussed the various molecular subtyping in the trials using PARP inhibitors. 

The discussion/conclusion could use additional contents in how molecular subtyping and precision medicine approaches can be applied in trials. 

In table 2, key effective results section for NCT0197 2217 (46), no HR,CI and p-value was provided for median PFS2 and median OS. 

Author Response

Please see the attachment 

Author Response File: Author Response.docx

Reviewer 2 Report

 

In the present review titled ‟Clinical Application of Poly (ADP-ribose) polymerase (PARP) Inhibitors in Prostate Cancer”, authors thoroughly summarized the PARP family members, their inhibitors and different therapeutic strategies to treat Stage IV (metastatic) prostate cancer using PARP inhibitors alone or in combination with other agents. The manuscript is well-written and easy to follow. Authors included latest data especially clinical trials is very informative and fine detailed. This review provides an easy and clear understanding of PARP inhibitors and their scope in developing new therapeutics for metastatic castrate resistant prostate cancer (mCRPC).

 

I recommend this article is suitable for publication. 

 

Author Response

Please see the attachment 

Author Response File: Author Response.docx

Reviewer 3 Report

This is a very important and interesting review summarizing and critically discussing knowledge on clinical application of Poly (ADP-ribose) polymerase (PARP) inhibitors in prostate cancer. The Review is complete and well presented.

I think that it can be accept in present form.

Author Response

Please see the attachment 

Author Response File: Author Response.docx

Back to TopTop